Latest News
More Costly, Polarized Dermatoscope Results Compared to Nonpolarized Dermatoscope
10 minutes ago
This randomized study explored a lower-cost, ambient-light, nonpolarized dermatoscope and its clinical utility in patient-performed teledermoscopy.
Mechanistic Roles of Transthyretin Silencers and Stabilizers in ATTR-CM
1 hour ago
The panel reviews the two major therapeutic strategies for treating ATTR-CM: transthyretin (TTR) silencers and stabilizers. Stabilizers work by binding to the TTR protein and preventing it from misfolding into amyloid fibrils, helping maintain the protein’s native structure. Silencers, by contrast, act at the genetic level to reduce the production of TTR protein in the liver through RNA interference or antisense mechanisms. Together, these approaches aim to reduce amyloid formation and slow disease progression. The experts note that patients are often highly informed and eager to understand the differences between these therapies. They emphasize the importance of clear, patient-centered discussions that explain how the treatments work, why both options exist, and how therapy selection may depend on disease stage, phenotype, genetic background, and emerging clinical evidence. As research evolves, clinicians continue to refine how these mechanisms complement one another and how combination or sequential strategies may shape future care.
Selectivity of TYK2 Inhibition in Psoriasis
1 hour ago
Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.
Targeting IL-23 and IL-17 in Psoriatic Disease: Pathways to Inflammation Control and PsA Prevention
1 hour ago
In this episode, the panelists focus on the IL-23 and IL-17 pathways and their influence on inflammation control and psoriatic arthritis (PsA) prevention. The experts explain that IL-23 sits at the top of the inflammatory cascade, driving Th17 cell activation and downstream cytokine release. They note that inhibiting IL-23 can lead to long-term immunologic remission and possibly modify PsA progression, given its infrequent dosing and favorable safety profile. The discussion compares IL-23 and IL-17 inhibition, highlighting that while IL-23 blockade targets disease upstream, IL-17 acts as the “enforcer” cytokine driving local joint and skin inflammation. The panelists review emerging data showing that dual inhibition of IL-17A and IL-17F, as achieved with newer biologics, may provide more robust and durable skin clearance than targeting IL-17A alone. They conclude that deeper inflammation control through these pathways could reduce PsA risk and sustain long-term disease remission.
Unmet Needs in ATTR-CM Care
1 hour ago
The panel shifts to remaining unmet needs in ATTR-CM care, emphasizing that despite progress in diagnosis and available therapies, gaps persist across patient identification, treatment access, and long-term management. One ongoing challenge is recognizing early disease and distinguishing ATTR-CM from other common cardiac conditions, particularly in older adults with preserved ejection fraction. The experts stress that clinicians must think beyond labeling HFpEF as a final diagnosis by seeking its underlying cause. Therapeutically, the group notes that while stabilizers and silencers have expanded treatment options, navigating these therapies requires careful consideration of patient characteristics, tolerance, and evolving evidence. Cost and access barriers continue to affect who receives treatment and when. The panel also highlights the need for more data on disease monitoring and response assessment, particularly regarding biomarkers and imaging changes over time. Finally, greater patient and provider education, coordinated care pathways, and earlier referrals remain essential to improving outcomes.